{"id":19092,"date":"2026-08-17T05:22:54","date_gmt":"2026-08-17T08:22:54","guid":{"rendered":"https:\/\/rtmedical.com.br\/tmp-en-1786954974097\/"},"modified":"2026-08-17T05:23:02","modified_gmt":"2026-08-17T08:23:02","slug":"fda-approves-tau-pet-alzheimers","status":"publish","type":"post","link":"https:\/\/rtmedical.com.br\/en\/fda-approves-tau-pet-alzheimers\/","title":{"rendered":"FDA Approves Lantheus Tau PET Agent for Alzheimer’s"},"content":{"rendered":"

The FDA has approved Tauklarify (florquinitau F 18), a PET tracer built to identify tau neurofibrillary tangle pathology in the brains of adults with cognitive impairment being evaluated for Alzheimer’s disease. Lantheus announced the approval on August 14, giving the US market its second registered tau tracer<\/strong> \u2014 the first, flortaucipir, arrived in 2020 \u2014 just days after Lantheus itself signed a definitive agreement to be acquired by Curium.<\/p>\n

What the approval covers, and what it does not<\/h2>\n

The indication is deliberately narrow: brain PET in adults with cognitive impairment under evaluation for Alzheimer’s disease, for the purpose of identifying patients with tau neurofibrillary tangle (NFT) pathology. Safety and effectiveness have not<\/strong> been established for evaluating other brain diseases \u2014 which in practice excludes non-Alzheimer’s tauopathies such as progressive supranuclear palsy and corticobasal degeneration.<\/p>\n

\"Clinician
Neuroimaging review gains a molecular layer with tau tracers. Photo: MART PRODUCTION\/Pexels<\/figcaption><\/figure>\n

Also known by the development code MK-6240, the compound reached Lantheus through rights acquired from Enigma Biomedical USA in 2023, with the two companies continuing to collaborate on clinical development. The Bedford, Massachusetts-based company said safety was assessed in two clinical trials spanning more than 1,700 subjects, with fewer than 1% reporting adverse reactions.<\/p>\n

How the efficacy package was assembled<\/h2>\n

This is the part that matters to whoever reads the scans. Approval rested on two blind-read studies analyzing PET images from more than 500 subjects who had participated in three clinical trials. The sample was deliberately broad: patients with mild cognitive impairment, patients with mild Alzheimer’s disease dementia, and cognitively unimpaired comparison subjects. The point was to span the full functional spectrum, early-stage disease included.<\/p>\n

All received an intravenous dose of roughly 185 MBq (5 mCi)<\/strong> before acquisition. Scans were interpreted by independent readers, specifically trained in image interpretation and blinded both to clinical information and to amyloid beta PET results. Each study was classified positive or negative for tau NFT pathology and compared against a preestablished reference standard built from cognitive status and amyloid beta PET findings.<\/p>\n

“Today’s approval of Tauklarify reflects both the increasing importance of tau imaging in Alzheimer’s disease assessment and the innovative development program that supported this milestone,” said Mary Anne Heino, CEO and executive chair of Lantheus. “We remain committed to advancing research that will further define the role of tau imaging in understanding Alzheimer’s disease.”<\/p>\n

Why tau matters more than amyloid for prognosis<\/h2>\n

The biology is worth unpacking, because it explains the clinical value. Alzheimer’s pathology has two central protein markers: beta-amyloid plaques and neurofibrillary tangles of hyperphosphorylated tau. Amyloid appears early and is relatively indifferent to symptom severity \u2014 plenty of cognitively normal people have a positive amyloid PET. Tau is a different story: its distribution follows a stereotyped anatomical pattern, described by Braak staging, advancing from transentorhinal and entorhinal regions into the limbic system and then the neocortex.<\/p>\n

That progressive pattern is exactly what makes tau imaging useful. Tau burden and distribution correlate far better with clinical severity and rate of cognitive decline than amyloid burden does. Under the revised biological criteria for Alzheimer’s diagnosis, amyloid serves as the disease-defining marker while tau PET takes on staging and prognosis \u2014 it answers “how advanced,” not merely “yes or no.”<\/p>\n

One technical detail favors MK-6240 over the first-generation tracer: lower off-target binding. Flortaucipir has known nonspecific uptake in choroid plexus, basal ganglia, and monoamine oxidase-rich structures, which complicates reading the medial temporal regions \u2014 precisely where early tau settles. A cleaner tracer in that anatomical band makes early disease easier to detect.<\/p>\n

Practical implications and market context<\/h2>\n

The most immediate use is not diagnosis but treatment selection. The anti-amyloid antibodies that entered clinical use in recent years show heterogeneous benefit depending on tau burden, and phase 3 trials have already stratified patients by tau PET into low\/medium versus high burden groups. When the decision to infuse an expensive antibody carrying a risk of edema and microhemorrhage hinges on tau stage, molecular imaging stops being a confirmatory test and becomes an eligibility criterion.<\/p>\n

Commercially, expectations are modest. Tau imaging today is dominated by the 2020-approved product, which brings in less than $100 million a year; forecasts for Tauklarify point to under $50 million annually by 2030. It is a niche \u2014 but a strategic niche inside a radiopharmaceutical portfolio, which ties directly to Curium’s move to buy Lantheus<\/a>, formalized in a definitive agreement in early August and valued at up to $8 billion.<\/p>\n

For nuclear medicine departments, the operational challenge is the usual one with fluorine-18: a half-life of roughly 110 minutes demands tight delivery logistics and block scheduling. Nothing new for anyone already running amyloid or FDG PET, but the acquisition protocol and regions of interest differ, and the reader learning curve is real \u2014 the FDA itself required reader-specific training in the pivotal studies. Anyone following the theranostics and molecular imaging agenda saw this coming at this year’s SNMMI meeting<\/a>.<\/p>\n

Limitations and what comes next<\/h2>\n

Three honest caveats. The first is already on the label: validation applies to Alzheimer’s, not to the differential diagnosis of non-Alzheimer’s tauopathies, and using the scan outside that indication is extrapolation. The second is methodological: the reference standard in the pivotal studies combined cognitive status and amyloid PET, not neuropathology \u2014 comparison against autopsy remains the harder test. The third is access: tau PET is not yet part of routine clinical care across most of the world outside the United States, and in many markets amyloid tracers circulate in only a handful of centers while tau stays essentially confined to research.<\/p>\n

Even so, the direction mirrors what molecular imaging has been doing in oncology: moving from confirming a suspicion to stratifying risk and steering therapy. Tau imaging has already proven, in other contexts, that it can see proteinopathy in living patients \u2014 we covered the use of tau PET to detect signs of chronic traumatic encephalopathy in living subjects<\/a>. A second approved tracer expands production capacity, introduces price competition, and above all reduces the risk of single-supplier dependence for a scan that is starting to function as a treatment prerequisite.<\/p>\n

Source:<\/strong> Radiology Business \u2014 FDA approves new Alzheimer’s PET imaging agent from Lantheus<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The FDA approved Tauklarify, Lantheus’ tau PET agent for Alzheimer’s. Inside the indication, the trial data and clinical use.<\/p>\n","protected":false},"author":1,"featured_media":19072,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"ngg_post_thumbnail":0,"_rt_cluster":"","fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[100],"tags":[],"class_list":["post-19092","post","type-post","status-publish","format-standard","has-post-thumbnail","category-radiology"],"aioseo_notices":[],"rt_seo":{"title":"","description":"The FDA approved Tauklarify, Lantheus' tau PET tracer for Alzheimer's. Indication, pivotal study data and clinical use.","canonical":"","og_image":"","robots":"index,follow","schema_type":"Article","include_in_llms":true,"llms_label":"FDA approves Tauklarify tau PET","llms_summary":"The FDA approved Lantheus' Tauklarify (florquinitau F 18, formerly MK-6240) for brain PET to identify tau NFT pathology in adults with cognitive impairment evaluated for Alzheimer's disease; it is the second registered tau tracer in the US.","faq_items":[],"video":[],"gtin":"","mpn":"","brand":"","aggregate_rating":[]},"_links":{"self":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/19092\/"}],"collection":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/"}],"about":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/types\/post\/"}],"author":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/users\/1\/"}],"replies":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/comments\/?post=19092"}],"version-history":[{"count":1,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/19092\/revisions\/"}],"predecessor-version":[{"id":19094,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/19092\/revisions\/19094\/"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/media\/19072\/"}],"wp:attachment":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/media\/?parent=19092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/categories\/?post=19092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/tags\/?post=19092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}